Spondyloarthritis & psoriatic arthritis
Four-year effectiveness, safety and drug retention rate of secukinumab in psoriatic arthritis: a real-life Italian multicenter cohort
Authors' conclusion
Secukinumab proved safe and effective, and patients achieved sustained remission with a notable drug retention rate at 4 years.
Study context
- Population
- Consecutive PsA patients receiving secukinumab, Italian centers, 2016–202342.5% male
- Participants
- 685 patients
- Exposure
- bDMARD-naïve vs non-naïve; by number of comorbidities
- Outcome
- Long-term effectiveness (MDA, DAPSA remission/LDA), safety and DRR of secukinumab
- Follow-up
- 48 months (T48)
Methodological detailsmulticentre, real-life
- Multicentre
- Real-life
Main finding
As reported in the abstract
DAPSA at T48 · up to 48 months
DAPSA at T48 · up to 48 months Naïve 4.0 (range or IQR as printed 1.4–8.1) · Non-naïve 6.0 (range or IQR as printed 2.2–10.4)
MDA
- Naïve vs Non-naïve: P = 0.04
- Overall drug retention rate (DRR) at T48
- 66%
Observational data: associations, not effects.
Further findings
MDA by comorbidities · up to 48 months — No comorbidities vs 1-3 comorbidities
P < 0.05
| Outcome | P value |
|---|---|
| MDA by comorbidities · up to 48 monthsNo comorbidities vs > 3 comorbidities | P < 0.001 |
MDA by comorbidities · up to 48 months
- DAPSA-REM and DAPSA-LDA similar without vs 1-3 comorbidities, slightly lower with > 3 comorbidities
Safety
Discontinuation
- Discontinued due to adverse events (AE)
- 41
- Discontinued due to loss of effectiveness
- 233
Original publication
Four-year effectiveness, safety and drug retention rate of secukinumab in psoriatic arthritis: a real-life Italian multicenter cohort. Arthritis Res Ther. Published 28 September 2024. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →